Your session is about to expire
← Back to Search
PCI-32765 for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 201 Patients • NCT03053440Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never taken PCI 32765 or any BTK inhibitors.I need to take warfarin for blood thinning.I need medication that strongly affects liver enzymes.I am not pregnant, breastfeeding, and willing to follow birth control measures.I understand the study's purpose and can give informed consent.I haven't had any CLL treatments like chemotherapy in the last 4 weeks.I am HIV positive.My CLL has transformed into a more aggressive form.I am 65 or older and need treatment.I am over 18 and have cancer with specific genetic changes.I have a confirmed diagnosis with high B-cell counts or confirmed lymph node involvement.I am under 18 years old.I have an autoimmune blood disorder treated with steroids.My liver function tests are higher than normal, but it's not because of Gilbert's disease or liver infiltration.My kidney function is reduced with high creatinine or low GFR.I don't have any severe illnesses that could affect my safety in the study or interfere with the study drug.I am not currently on high-dose steroids or undergoing cancer treatments.I have an active Hepatitis B infection.
- Group 1: Elderly greater than 65
- Group 2: 17p Deletioin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has PCI 32765 been permitted by the FDA?
"According to Power's safety scale, PCI 32765 scored a 2 due to the presence of Phase 2 trial data indicating some level of security; however, there is no evidence validating its efficacy."
Is the enrollment process for this trial still available to individuals?
"Unfortunately, this trial is no longer recruiting participants. Initially posted on November 28th 2011 and last updated December 2nd 2021, the study has successfully been completed. Nevertheless, there are over 3000 other studies searching for candidates at present."
What is the numerical extent of individuals engaging in this research?
"At this moment, no new patients are being sought for this clinical trial. It was initially posted on November 28th 2011 and the last edit occurred December 2nd 2021. Alternatively, there are currently 2864 trials accepting participants with a diagnosis of leukemia and 155 studies enrolling those administered PCI 32765 as part of their treatment plan."
Share this study with friends
Copy Link
Messenger